Last reviewed · How we verify
Sodium Chloride 0.9% Intravenous Solution
Sodium chloride 0.9% restores and maintains electrolyte balance and fluid volume in the body by providing isotonic saline solution.
Sodium chloride 0.9% restores and maintains electrolyte balance and fluid volume in the body by providing isotonic saline solution. Used for Fluid and electrolyte replacement in dehydration, Maintenance of fluid balance during surgery or acute illness, Vehicle for intravenous medication administration.
At a glance
| Generic name | Sodium Chloride 0.9% Intravenous Solution |
|---|---|
| Also known as | placebo comparator, Physiologic saline |
| Sponsor | Department of Medical Services Ministry of Public Health of Thailand |
| Drug class | Electrolyte replacement solution |
| Modality | Small molecule |
| Therapeutic area | Fluid and electrolyte management |
| Phase | FDA-approved |
Mechanism of action
This intravenous solution contains sodium and chloride ions in physiologic concentration (0.9% w/v), matching the osmolality of blood plasma. It is used to replace lost fluids and electrolytes, maintain hydration, and serve as a vehicle for administering other medications. The isotonic nature prevents cell lysis or crenation.
Approved indications
- Fluid and electrolyte replacement in dehydration
- Maintenance of fluid balance during surgery or acute illness
- Vehicle for intravenous medication administration
- Treatment of hypovolemia and shock
Common side effects
- Hyperchloremic acidosis
- Fluid overload
- Hypernatremia
- Phlebitis at injection site
Key clinical trials
- Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC) (PHASE2, PHASE3)
- Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal Histologies (PHASE1)
- Long-term Outcomes of Lidocaine Infusions for Post-Operative Pain (LOLIPOP) Trial (PHASE3)
- Bleeding Reduction in Acute and Chronic Kidney Patients Having Surgery (BRACKETS) Pilot Trial (PHASE3)
- Intravenous Lidocaine Infusion in Lumbar Fusion Surgery (NA)
- Phase 2b Study to Investigate the Safety and Efficacy of TIN816 in Sepsis-associated Acute Kidney Injury (CLEAR-AKI) (PHASE2)
- Angiotensin II in Liver Transplantation (PHASE2, PHASE3)
- The Effects of Intraoperative Tranexamic Acid on Perioperative Bleeding In Craniotomies (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: